**Core tip:** The ability of ultrasound-guided prostate biopsy to detect prostate cancer is limited. Maybe prostate biopsy can be exempt before surgery when multi-parameter prostate magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography/computed tomography are both positive. The current practice of mandating a prostatic biopsy before prostatectomy should be reconsidered in the era of new imaging technology and minimally invasive techniques.

INTRODUCTION
============

Prostate cancer is one of the most common malignancies worldwide. The current methods for diagnosing prostate cancer include digital rectal examination (DRE), serum prostate specific antigen (PSA), transrectal prostate ultrasound, and magnetic resonance imaging (MRI). Routinely, after receiving one or more of these tests, patients with suspected prostate cancer are required to undergo prostate biopsy. However, the sensitivity of ultrasound-guided prostate biopsy is approximately 48%\[[@B1]\]. While clinically insignificant cancers are often detected, clinically significant cancers are sometimes missed after prostate biopsy\[[@B2],[@B3]\]. Transrectal ultrasound guided (TRUS)-biopsy also carries significant morbidity and can cause life-threatening sepsis\[[@B4]\]. Nowadays, we have a variety of diagnostic methods and more sensitive diagnostic methods, such as multi-parameter prostate magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen positron emission tomography /computed tomography (PSMA PET/CT). The reported sensitivity of mpMRI for the detection of clinically significant disease was 93% (95%CI: 88%-96%)\[[@B1]\], and ^68^Gallium-PSMA PET/CT had a 100% detection rate for index lesions at radical prostatectomy\[[@B5]\]. Furthermore, laparoscopic/robot-assisted prostatectomy is also a safe and effective procedure for the treatment of benign prostatic hyperplasia\[[@B6]\]. To take all the above-mentioned factors together, we hypothesized that it might be no longer necessary to perform prostate biopsy before radical prostatectomy.

In this study, we summarized 11 cases of radical prostatectomy without prostate biopsy from three tertiary hospitals to explore the feasibility of radical prostatectomy without prostate biopsy.

MATERIALS AND METHODS
=====================

Clinical data
-------------

Between June 2014 and December 2018, five, three, and three cases of laparoscopic radical prostatectomy were performed without prostate biopsy before surgery at National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences, Beijing Chaoyang Hospital Affiliated to Capital Medical University, and Shandong Provincial Hospital, respectively. All surgeries were performed by the same surgeon who had high volume experience of laparoscopic surgeries. All patients received serum PSA test, digital rectal examination, transrectal prostatic ultrasound, and MRI of the prostate, and six of them received ^68^Ga-PSMA PET/CT examination. Informed consent was obtained before surgery to fully communicate with patients and family members, and to explain possible surgical risks especially postoperative pathology. Data were collected, including patient demographics, perioperative outcomes, pathological results, and complications. Postoperative complications were graded using the Clavien classification method, and the complications were classified into minor (Clavien grade I-II) and major (Clavien grade III-V)\[[@B7]\].

Surgical technique
------------------

All surgeries were carried out using an extraperitoneal approach and five trocar technique as we described before\[[@B8]\]. After creating a working space via an extra- peritoneal approach, the prostate, bladder, and endopelvic fascia were exposed. The endopelvic fascia was incised on both sides, and blunt dissection was performed towards the apex of the prostate. The puboprostatic ligaments were preserved, and the dorsal venous complex was ligated using a 2/0 v-lok suture. The bladder neck was carefully dissected and preserved followed by dissection of the seminal vesicles and incision of the Denonvillier's fascia. The prostatic pedicles were clipped close to the prostate and cut with cold scissors step by step. Apical dissection of the prostate and division of the urethra were then performed. The urethra was cut at the middle between the external urethral sphincter and the apex of the prostate with cold scissors. Bilateral pelvic lymph node dissection was performed in all patients. All specimens were removed in a retrieval endobag.

The "sandwich" reconstruction technique was utilized during the urethrovesical anastomosis\[[@B8]\]. First, the posterior reconstruction was accomplished by two-layer suturing including the Denonvillier's fascia with the median dorsal raphe (MDR) and the posterior wall of the bladder with the MDR. The second step of the reconstruction was the urethrovesical anastomosis. The third step was anterior reconstruction consisting of reattachment of the puboprostatic ligaments with the detrusor apron of the bladder.

RESULTS
=======

All surgeries were successfully accomplished without open conversion. The patient characteristics and pathologic outcomes are shown in Table [1](#T1){ref-type="table"}.

###### 

Patient characteristics and pathologic outcomes

  **Case**   **Age (yr)**   **BMI** **(kg/m^2^)**   **Maximum PSA (ng/mL)**   **Prostate volume**   **MRI**   **PET/CT**   **Bone scan**   **Pathology tumor stage**      **Gleason score**   **Positive lymph nodes**
  ---------- -------------- ----------------------- ------------------------- --------------------- --------- ------------ --------------- ------------------------------ ------------------- --------------------------
  1          61             25.4                    8.6                       40                    \+        /            /               T3aN0                          3 + 4 = 7           0
  2          71             25.3                    \>1000                    23                    \+        /            \+              T3bN0                          4 + 5 = 9           0
  3          62             24.5                    \>1000                    30                    \+        /            \+              T2cN1                          5 + 4 = 9           16/22
  4          76             25.3                    18.3                      80                    \+        /            /               T2cN0                          4 + 3 = 7           0
  5          79             22.4                    41.2                      20                    \+        \+           /               T2cN0                          5 + 5 = 10          0
  6          80             23.3                    15.2                      46                    \+        /            /               Benign prostatic hyperplasia                       0
  7          73             23.4                    27.7                      31                    \+        \+           /               T3aN0                          4 + 4 = 8           0
  8          56             23.2                    9.2                       41                    \+        \+           /               T2aN0                          3 + 3 = 6           0
  9          69             26.6                    22                        47                    \+        \+           /               T3aN0                          4 + 5 = 9           0
  10         67             24.5                    4.3                       27                    \+        \+           /               T2bN0                          3 + 4 = 7           0
  11         65             27.6                    15.9                      65                    \+        \+           /               T2cN0                          3+ 3 = 6            0

+: Positive. /: not receiving the test; BMI: Body mass index; PSA: Prostatic specific antigen; MRI: Magnetic resonance imaging; PET/CT: Positron emission tomography and computed tomography.

The mean age was 69 ± 7.7 year and the mean BMI was 24.7 ± 1.6 kg/m^2^. The range of serum PSA was 4.3 to \>1000 ng/mL and the mean prostate volume was 40.9 ± 18.3 mL. The mean operative time was 96 ± 23.3 min, the mean estimated blood loss was 90 ± 90.9 mL, and no patient required transfusion. The median time of catheter retention was 14 d. No major complications occurred in 90 d postoperatively.

The pathological results showed ten cases of prostatic adenocarcinoma and one case of benign prostatic hyperplasia. The pathologic tumor stage revealed pT2aN0 (1 case), pT2bN0 (1 case), pT2cN0 (3 cases), pT2cN1 (1 case), pT3aN0 (3 cases), and pT3bN0 (1 case) (Figure [1](#F1){ref-type="fig"}). One patient developed pelvic lymph node metastasis (16/22) and no lymph node metastasis was found in other patients. There were two cases with a Gleason score of (3 + 3 = 6) points, two with a score of (3 + 4 = 7) points, one with a score of (4 + 3 = 7) points, one with a score of (4 + 4 = 8) points, and four with a score ≥ 9 points. Two cases had positive margins at the prostatic base.

![Pathological images of prostate cancer.](WJCC-7-1403-g001){#F1}

DISCUSSION
==========

Prostate biopsy to exclude cancer has been part of clinical practice since the beginning of the 20^th^ century. The introduction of PSA and ultrasound into clinical practice in the 1980s and the evolution of mpMRI in the early 21^st^ century have driven the prostate biopsy into a more scientific-based procedure. Current practice mandates a prostate biopsy before radical prostatectomy, despite many complications such as urosepsis, urinary retention, and hematuria *etc*\[[@B9]\]. On the other hand, renal tumors are treated completely differently. When a renal tumor was highly suspected to be malignant by CT or MRI imaging, radical nephrectomy or partial nephrectomy is routinely carried out clinically. Renal tumor biopsy is not mandated before surgery currently\[[@B10]\].

Compared to radical nephrectomy and partial nephrectomy, the procedure of radical prostatectomy is more difficult and postoperative complications seriously affect the quality of life, such as urinary incontinence and erectile dysfunction. However, with accumulation of surgical experience, improvement of surgical techniques, and advancement of surgical equipment, minimally invasive radical prostatectomy has shorter operative time, less trauma, and faster recovery, and the early continence and erectile function recover faster than before\[[@B11]-[@B13]\]. Our previous data also showed that patients\' early urinary continence rate and quality of life were significantly improved after laparoscopic radical prostatectomy with the \"sandwich\" urethrovesical anastomosis technique\[[@B8]\].

The use of mpMRI and the PI-RADS prostate cancer scoring system has sig-nificantly improved the diagnostic accuracy of clinically significant prostate cancer\[[@B14],[@B15]\]. And there is evidence that mpMRI tends to detect higher risk disease and systematically overlooks low-risk disease\[[@B1],[@B14]\]. Ahmed et al\[[@B1]\] found that the sensitivity of mpMRI for the detection of clinically significant disease was 93% (95%CI: 88%-96%), which was significantly superior to the sensitivity of TRUS biopsy (48%; 95%CI: 42%-55%). One meta-analysis showed that the pooled sensitivity and speciﬁcity of mpMRI for prostate cancer detection are 74% and 88%, respectively\[[@B16]\]. Assessment of lymph node involvement can be performed by both CT and mpMRI, but both have a very low sensitivity\[[@B17]\].

The use of PSMA PET/CT further enhances the accuracy of diagnosing prostate cancer, not only to assess primary lesions but also to assess metastases. Berger et al\[[@B5]\] compared the accuracy of ^68^Ga-PSMA PET/CT and mpMRI in assessing prostate cancer and found that ^68^Ga-PSMA PET/CT had a 100% detection rate for index lesions at radical prostatectomy. Six patients in our study underwent ^68^Ga-PSMA PET/CT and the detection rate was 100%, which was confirmed by final pathology. Besides primary lesion, PSMA PET/CT also had a high specificity and moderate sensitivity for lymph node metastasis detection for patient with intermediate- to high-risk prostate cancer\[[@B18]\]. It is more accurate than morphologic imaging for detection of lymph node metastasis\[[@B19]\]. Until now, no prospective study accesses the oncologic efficacy of PSMA PET/CT guided lymph node dissection compared to conventional strategy.

One lesion by lesion analysis showed that combination of ^68^Ga-PSMA PET/CT and multiparameter MRI can improve the detection of clinically significant prostate cancer\[[@B20]\]. We recommend every patient being suspected of having prostate cancer to receive mpMRI and PSMA PET/CT which could help surgeons to detect clinically significant prostate cancer, and prostate biopsy can be exempt before surgery when both imaging tests are positive.

The critical concern for radical prostatectomy without biopsy is overtreatment if the pathology turns to be benign. However, the prostate is not a vital organ for the elder man. Rather it may lead to risks such as benign prostate hyperplasia and prostate cancer which influence the quality of life. Surgery is an optional treatment modality for both benign prostate hyperplasia and prostate cancer. While benign prostate hyperplasia is mostly operated by the transurethra procedure, laparoscopic and robot-assisted laparoscopic surgeries are also indicated in some patients. One meta-analysis study showed that open, laparoscopic, and robot-assisted laparoscopic surgeries can safely complete simple prostatectomy\[[@B21]\]. One study comparing transurethral holmium laser enucleation of the prostate with robot-assisted simple prostatectomy showed that both procedures can effectively treat benign prostatic hyperplasia\[[@B22]\]. Although the transurethral laser ablation procedure had shorter operation time, less blood loss, and shorter hospital stay, there was no significant difference in the major compli-cations or postoperative urinary continence. One of our cases was benign prostate hyperplasia. The patient was very satisfied with the treatment since he recovered very well without major complications, while his lower urinary tracts symptoms disappeared. Therefore, it is acceptable even the final pathology is benign for some patients who received radical prostatectomy.

In summary, the current practice of mandating a prostatic biopsy before prosta-tectomy should be reconsidered in the era of new imaging technology and minimally invasive techniques. Radical prostatectomy could be carried out without the evidence of malignancy. Large-sample randomized controlled trials are definitely required to confirm the feasibility of this new concept.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Prostate cancer is one of the most common malignant tumors. When the total PSA and/or digital rectum examination are positive, prostate biopsy is routinely proposed to patients. However, the detection ability of the transrectal ultrasound guided (TRUS) prostate biopsy is limited. While clinically insignificant cancers are often detected, clinically significant cancers are sometimes missed after prostate biopsy. TRUS-biopsy also carries significant morbidity and can cause life-threatening sepsis. The reported sensitivity of multi-parameter prostate magnetic resonance imaging for the detection of clinically significant disease was 93% (95%CI 88-96), and ^68^Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography had a 100% detection rate for index lesions at radical prostatectomy.

Research motivation
-------------------

Nowadays, many imaging techniques with a very high detection rate for prostate cancer are applied clinically. Some patients are afraid of prostate biopsy, and they really want to remove the prostate immediately when they were told that they might have prostate cancer. For elder men, laparoscopic/robot-assisted prostatectomy is also a safe and effective procedure for the treatment of benign prostatic hyperplasia. So it might be no longer necessary to perform prostate biopsy before radical prostatectomy.

Research objectives
-------------------

The main objective of the study was to explore the feasibility of radical prostatectomy without prostate biopsy in the era of new imaging technology and minimally invasive techniques.

Research methods
----------------

A retrospective study was designed. The cases of laparoscopic radical prostatectomy without prostate biopsy before surgery were collected at the three medical centers involved in this study between June 2014 and December 2018. The perioperative outcomes and pathology results were analyzed.

Research results
----------------

All surgeries were successfully accomplished without open conversion. The pathological results showed ten cases of prostatic adenocarcinoma and one case of benign prostatic hyperplasia. Lower urinary tract symptoms disappeared when the patient with benign prostatic hyperplasia underwent laparoscopic radical prostatectomy.

Research conclusions
--------------------

The current practice of mandating a prostatic biopsy before prostatectomy should be reconsidered in the era of new imaging technology and minimally invasive techniques. Radical prostatectomy could be carried out without the evidence of malignancy.

Research perspectives
---------------------

It might be no longer necessary to perform prostate biopsy before radical prostatectomy. However, large-sample randomized controlled trials are definitely required to confirm the feasibility of this new concept.
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